Groups | Treatment | Protein in splenic tissue (mg/ml) | LPO (nM MDA/g tissue) | SODa (U/ mg of protein) | Catalase (mM H2O2 utilized/min mg of protein) | GSH (mM GSH/g tissue) | GSTa(μM of CDNB-GSH conjugate min-1 mg-1 protein) | GPx (nM NADPH utilized/min/mg protein) |
---|---|---|---|---|---|---|---|---|
I | Control | 3.42 ± 0.56 a | 50.56 ± 1.60a | 3.93 ± 0.35a | 85.32 ± 7.35a | 2.38 ± 0.21abc | 1.62 ± 0.12a | 1.93 ± 0.35a |
II | Vehicle control (Corn oil) | 4.05 ± 1.02 a | 61.78 ± 2.12ab | 4.16 ± 0..36a | 79.07 ± 10.61a | 2.48 ± 0.17ab | 1.74 ± 0.14a | 0.96 ± 0.37ab |
III | α-tocopherol (100 mg/kg) | 3.21 ± 0.41 a | 68.56 ± 8.08ab | 3.33 ± 0.40ab | 87.94 ± 9.15a | 2.49 ± 0.08a | 1.66 ± 0.15a | 0.59 ± 0.06ab |
IV | Copper sulphate (33 mg/kg) | 2.59 ± 0.32 a | 81.65 ± 4.08b | 1.82 ± 0.25b | 80.54 ± 7.29a | 1.91 ± 0.04abc | 1.65 ± 0.20a | 0.49 ± 0.04b |
V | Flubendiamide (200 mg/kg) | 3.69 ± 0.61 a | 81.70 ± 5.57b | 3.40 ± 0.38a | 60.37 ± 7.99a | 1.84 ± 0.00c | 0.61 ± 0.12b | 0.37 ± 0.06 b |
VI | Copper sulphate (33 mg/kg) + Flubendiamide (200 mg/kg) | 2.30 ± 0.34 a | 75.06 ± 7.67b | 3.27 ± 0.34ab | 98.76 ± 10.80a | 1.96 ± 0.12abc | 1.34 ± 0.25a | 0.43 ± 0.11b |
VII | Copper sulphate (33 mg/kg) + α-tocopherol (100 mg/kg) | 2.81 ± 0.37 a | 77.13 ± 10.74b | 3.02 ± 0.25ab | 83.48 ± 8.79a | 1.87 ± 0.09bc | 1.50 ± 0.09a | 1.16 ± 0.45ab |
VIII | Flubendiamide (200 mg/kg) + α-tocopherol (100 mg/kg) | 4.16 ± 0.52 a | 61.14 ± 6.50ab | 4.42 ± 0.40a | 61.74 ± 10.55a | 2.19 ± 0.19abc | 1.43 ± 0.15a | 0.68 ± 0.36ab |
IX | Copper sulphate (33 mg/kg) + Flubendiamide (200 mg/kg)) + α-tocopherol (100 mg/kg) | 2.85 ± 0.27 a | 68.96 ± 4.84ab | 3.05 ± 0.37ab | 81.40 ± 7.19a | 2.24 ± 0.10abc | 1. 95 ± 0.30a | 1.09 ± 0.48ab |